StayCurrentMD
Thrombosis
Everything in the library about thrombosis — built automatically from the recorded discussions that name it
Educational content from recorded physician discussions — not medical advice. Always talk to your child's care team about your child's situation.
Content of this collection
Medical Management
1 item
How do we manage thrombogenicity and thrombosis in the Fontan? New Horizons...
Watch →
Physicians from theCincinnati Children’s Heart Institutediscuss the long-term care of single ventricle patients from infancy to adulthood, including new insights on Fontan management and quality of life.During this session, Dr. Joseph Palum
video16:51 · Jan 2019
Surgical Management
2 items
Pediatric Vascular Access in Brief: Preoperative, Operative, and Postoperative Considerations
Watch →
All surgeons need to know about vascular access. Here we review some preoperative, operative, and postoperative considerations of pediatric vascular access with Dr. Alex Bondoc from Cincinnati Children's Hospital, including indications, con
video13:54 · Sep 2022
Pediatric Vascular Access
Listen →
podcast35:43 · Nov 2022
Summaries and takeaways+ Show
The doctors in this collection+ Show
All expert statements+ Show
Every expert statement below comes from the recorded discussions, with its speaker and moment.
How do we manage thrombogenicity and thrombosis in the Fontan? New Horizons...
Fontan circulation is a profoundly prothrombotic state and thrombosis is a major cause of death in patients with Fontan circulation.
clinicalJoe1:01 ↗
Many thrombotic events in Fontan patients are subclinical but clinically significant.
clinicalJoe1:10 ↗
The prevalence of silent pulmonary embolism in adults with Fontan circulation may be as high as 1 in 5 (20%).
host_summaryJoe1:23 ↗
In Paul Monagle's study comparing aspirin and warfarin in newer style Fontans, patients had an overall cumulative risk of 22% for thrombotic events.
host_summaryJoe1:39 ↗
The cumulative hazard risk of thrombotic events in Fontan patients increases over time, with Fontan circulation becoming essentially a freight train of thrombogenicity.
clinicalJoe2:19 ↗
Fontan circulation's thrombotic risk is comparable to paroxysmal nocturnal hemoglobinuria (30-40% risk over 5 years), antiphospholipid antibody syndrome, and unprovoked venous thromboembolism (20-30% recurrence rate).
clinicalJoe2:41 ↗
Relative hypoxia and loss of pulsatile flow in the venous system is very thrombogenic for endothelial cells.
clinicalJoe4:52 ↗
Hypoxia and loss of pulsatile flow result in upregulation of tissue factor expression (the primary initiator of the clotting cascade), upregulation of adhesion molecules that activate inflammatory cells, and increased secretion of factor VIII and von Willebrand factor.
clinicalJoe5:01 ↗
Protein-losing enteropathy (PLE) results in increased inflammatory system activation in Fontan patients.
clinicalJoe5:17 ↗
Liver synthetic dysfunction can develop over time in Fontan patients and worsen hemostatic system activation.
clinicalJoe5:22 ↗
Overall data supports that warfarin is better thromboprophylaxis than aspirin in Fontan patients.
clinicalJoe6:05 ↗
Reanalysis of Monagle's data showed that warfarin with time-in-therapeutic-range of 60% or better edged out aspirin over time.
host_summaryJoe6:14 ↗
Retrospective data from Cedric Manliot's group showed warfarin was clearly better than aspirin, though both were significantly better than no thromboprophylaxis.
host_summaryJoe6:39 ↗
Excellent time-in-therapeutic-range above 80% with warfarin is achievable using a paternalistic approach with aggressive monitoring and phone follow-up.
clinicalJoe7:05 ↗
In patients with excellent time-in-therapeutic-range (>80%), Grushin's group observed only one thrombotic event over 53 patient-years.
host_summaryJoe7:14 ↗
Even with well-managed anticoagulation, the bleeding risk is around 2% per year.
epidemiologicalJoe8:33 ↗
Warfarin is very problematic from a pharmacokinetic standpoint and poorly managed warfarin may actually increase thrombotic risk.
clinicalJoe8:43 ↗
Direct oral anticoagulants (DOACs) such as rivaroxaban and apixaban seem superior to warfarin in many ways but are completely unproven in Fontan patients.
clinicalJoe8:52 ↗
Thrombotic risk in Fontan patients follows a bimodal incidence: initial post-surgical risk, then a honeymoon phase of variable duration, followed by inexorable increase in thrombotic risk.
host_summaryJoe9:16 ↗
The honeymoon phase duration can vary and may be predictable using biomarkers.
opinionJoe9:40 ↗
Elevated D-dimer is a strong marker of increased thrombotic risk in adults with unprovoked venous thromboembolism.
host_summaryJoe10:08 ↗
Elevated factor VIII is a strong marker of increased thrombotic risk and can be elevated due to genetic factors, endothelial cell activation, or as an acute phase reactant indicating inflammation.
clinicalJoe10:17 ↗
Factor VIII activity increases significantly post-Fontan, and in one study the four patients with the highest factor VIII levels were the ones who developed thrombotic complications.
host_summaryJoe10:49 ↗
In Fontan patients, natural anticoagulants (antithrombin, protein C) are often lower, consistent with liver synthetic dysfunction developing over time.
host_summaryJoe11:10 ↗
Despite lower procoagulants from liver dysfunction, Fontan patients have elevated prothrombin fragment 1.2, indicating they are at thrombotic risk rather than bleeding risk.
host_summaryJoe11:46 ↗
Fontan circulation, even in the context of liver dysfunction, shifts the hemostatic balance toward a thrombophilic state.
clinicalJoe12:13 ↗
Monitoring D-dimer, factor VIII, liver function tests, and albumin every 6 months can predict when the honeymoon period of relatively low thrombotic risk is ending.
opinionJoe13:00 ↗
Aspirin VerifyNow is an extremely reliable and reproducible test that confirms patients are taking aspirin and having an antiplatelet response.
clinicalJoe14:40 ↗
DOACs need to be studied in the Fontan population before determining how good or bad they are.
opinionJoe15:26 ↗
To use DOACs routinely in Fontan patients, reliable monitoring methods are needed because organ function can change rapidly in these patients.
clinicalJoe15:36 ↗
What's new+ Show